The Use Of Intranasal (IN) Ketamine For Pain Control In Patients With Sickle Cell Disease And Vaso-occlusive Episode (VOE) In The Pediatric Emergency Department

About the study

This will be a descriptive cohort study of intranasal ketamine as the initial analgesic for children with sickle cell disease who present to the pediatric emergency department with vaso-occlusive crisis and are awaiting intravenous line placement.

Locations

2 United States sites

Age

3 to 25 Years

Genotypes

Hemoglobin SS

Phase

Phase 3

Study type

Interventional

Gender

All

Interventions

Drug

Compensation

Unknown

participation requirements

History of Hemoglobin SS or SC disease
Age 3 years old to 25 years old presenting to the PED with vaso-occlusive with moderate-severe pain determined at triage as pain score (FACES or numeric rating scale) ≥ 5
Parent or patient willing to provide consent/assent
English speaking

participation restrictions

Patient with concern for more severe complications including acute chest, splenic sequestration, sepsis, stroke, non-VOC pain, asthma exacerbation
Allergy to ketamine
GCS<15 Obstructive nasal anatomy as per parent history History of a psychiatric disorder Pregnant patients will be excluded. Female patients > 12 years old are routinely tested for pregnancy in our PED. Patients found to be pregnant will not be enrolled in study.

Locations

  • Bronx, New York, United States, Jacobi Medical Center, 10461 [Not yet recruiting]
  • Bronx, New York, United States, JACOBI, 10461 [Recruiting]
Last updated 2021-08-31